May 22, 2024
Preeclampsia Diagnostics Market

Preeclampsia Diagnostics Market to Progress Exponentially Due to Advancements in Biomarker Technologies

Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. It is a leading cause of maternal and fetal illness and death globally. Early detection and timely management can help reduce the risk of developing severe complications. The preeclampsia diagnostics tests help in the diagnosis of preeclampsia by detecting the presence of biomarkers like placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and endothelial cell-selectivity adhesion molecule (ESAM) through blood and urine tests.

The global preeclampsia diagnostics market is estimated to be valued at US$ 1828.84 Mn in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 to 2030.

Key Takeaways

Key players operating in the preeclampsia diagnostics market are The Dow Chemical Company, BASF SE, Covestro A.G., Huntsman Corp., Eastman Chemical Co., Mitsui Chemicals Inc, Recticel S.A., RTP Company Inc., Lubrizol Corp., Rampf Holding GmbH & Co. KG.

The rising prevalence of preeclampsia and gestational hypertension among expectant mothers presents lucrative opportunities for players in this market. Growing awareness about early diagnosis and the benefits it provides is another key growth driver.

Biomarker-based tests have emerged as an effective tool for early detection of preeclampsia. Advancements in technologies for biomarker detection are allowing for simple, affordable, and non-invasive diagnostics options. This is expected to boost the market significantly over the forecast period.

Market Drivers

One of the key drivers for the Preeclampsia Diagnostics Market Size is the increasing number of preterm births associated with preeclampsia. According to recent data, over 15 million babies are born preterm each year, and preeclampsia/eclampsia is responsible for around 25% of these. Moreover, preeclampsia is the second most common cause of maternal mortality after postpartum hemorrhage. Thus, the clinical need for more efficient diagnostics to improve health outcomes of both mother and baby is a major growth propeller. Other drivers include rising healthcare expenditure in emerging countries and growing awareness about the benefits of early detection of the condition. Improving access to screening and diagnostics services globally will also support market expansion.


Challenges in Preeclampsia Diagnostics Market

There are multiple challenges currently prevalent in the preeclampsia diagnostics market. Lack of accurate screening and diagnostic tests is a major issue in early detection of the condition. Early detection plays a crucial role in proper management of preeclampsia and improving maternal-fetal outcomes. However, currently available tests have low sensitivity and specificity, leading to missed or delayed diagnoses. Another challenge is the unclear etiology and pathophysiology of preeclampsia. The exact causes behind the onset of the condition are still unknown. This hinders development of novel targeted therapies and diagnostic techniques. affordability of available tests is another barrier, especially in low and middle-income countries. This deprives at-risk women from timely medical care.

SWOT Analysis
Strength: Non-invasive diagnostic techniques reduce pain and risk for patients. Early detection helps manage condition effectively.
Weakness: Available tests have low accuracy. Condition etiology is still unclear.
Opportunity: Rising preeclampsia incidence increases diagnostic needs. Novel biomarkers can enhance test sensitivity and specificity.
Threats: High cost of R&D for new tests. regulatory approvals are complex and lengthy.


Geographical Regions with High Market Concentration

North America currently dominates the preeclampsia diagnostics market in terms of value, owing to high healthcare expenditure and widespread healthcare infrastructure in the US and Canada. According to estimates, the North America regional market accounted for over 35% share of the global market in 2024. Europe is another leading regional market, driven by increasing awareness regarding maternal health, growing research on preeclampsia, and availability of diagnostic facilities across countries. The Asia Pacific region is projected to emerge as the fastest growing market during the forecast period, due to rising pregnancies coupled with improving access to diagnostic services. China, India and other developing nations will be key contributors to the region’s market growth trajectory.

Fastest Growing Geographical Region

The Asia Pacific regional market for preeclampsia diagnostics is expected to exhibit the highest growth rate during 2024-2030. This can be attributed to many factors. Rising birth rates and increasing awareness about hypertensive disorders in pregnancy are fueling demand. Governments of various Asia Pacific countries have undertaken initiatives to enhance maternal care infrastructure and make diagnostic facilities more affordable and accessible. This is positively impacting early screening and diagnoses. Economic development across the region has also improved healthcare investments and spending capabilities. The large patient pool offers attractive growth opportunities for market players. All these factors, coupled with expected regulatory approvals of novel diagnostic technologies, will support strong growth of the Asia Pacific preeclampsia diagnostics market over the coming years.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it